Literature DB >> 30731453

Antifibrotic Agent Pirfenidone Suppresses Proliferation of Human Pancreatic Cancer Cells by Inducing G0/G1 Cell Cycle Arrest.

Eri Usugi1, Kenichiro Ishii2, Yoshifumi Hirokawa1, Kazuki Kanayama3, Chise Matsuda1, Katsunori Uchida1, Taizo Shiraishi4, Masatoshi Watanabe1.   

Abstract

BACKGROUND: Pirfenidone (PFD), which is an antifibrotic agent used for treatment of idiopathic pulmonary fibrosis, induces G0/G1 cell cycle arrest in fibroblasts. We hypothesized that PFD-induced G0/G1 cell cycle arrest might be achieved in other types of cells, including cancer cells. Here we investigated the effects of PFD on the proliferation of pancreatic cancer cells (PCCs) in vitro.
METHOD: Human skin fibroblasts ASF-4-1 cells and human prostate stromal cells (PrSC) were used as fibroblasts. PANC-1, MIA PaCa-2, and BxPC-3 cells were used as human PCCs. Cell cycle and apoptosis were analyzed using flow cytometer.
RESULTS: First, we confirmed that PFD suppressed cell proliferation of ASF-4-1 cells and PrSC and induced G0/G1 cell cycle arrest. Under these experimental conditions, PFD also suppressed cell proliferation and induced G0/G1 cell cycle arrest in all PCCs. In PFD-treated PCCs, expression of p21 was increased but that of CDK2 was not clearly decreased. Of note, PFD did not induce significant apoptosis among PCCs.
CONCLUSIONS: These results demonstrated that the antifibrotic agent PFD might have antiproliferative effects on PCCs by inducing G0/G1 cell cycle arrest. This suggests that PFD may target not only fibroblasts but also PCCs in the tumor microenvironment of pancreatic cancer.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Antiproliferative effects; Fibroblasts; G0/G1 cell cycle arrest; Pancreatic cancer cells; Pirfenidone

Mesh:

Substances:

Year:  2019        PMID: 30731453     DOI: 10.1159/000496831

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  10 in total

1.  Pirfenidone inhibits epithelial-mesenchymal transition in keloid keratinocytes.

Authors:  Latha Satish; Alexander Evdokiou; Eleni Geletu; Jennifer M Hahn; Dorothy M Supp
Journal:  Burns Trauma       Date:  2020-02-27

2.  MCM2 and NUSAP1 Are Potential Biomarkers for the Diagnosis and Prognosis of Pancreatic Cancer.

Authors:  Yajun Deng; Hanyun Ma; Jinyong Hao; Qiqi Xie; Ruochen Zhao
Journal:  Biomed Res Int       Date:  2020-04-28       Impact factor: 3.411

3.  The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC.

Authors:  Sebastian Marwitz; Kati Turkowski; Dörte Nitschkowski; Andreas Weigert; Julius Brandenburg; Norbert Reiling; Michael Thomas; Martin Reck; Daniel Drömann; Werner Seeger; Klaus F Rabe; Rajkumar Savai; Torsten Goldmann
Journal:  Front Oncol       Date:  2020-01-21       Impact factor: 6.244

Review 4.  Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models.

Authors:  Marina Galicia-Moreno; Jorge A Silva-Gomez; Silvia Lucano-Landeros; Arturo Santos; Hugo C Monroy-Ramirez; Juan Armendariz-Borunda
Journal:  Can J Gastroenterol Hepatol       Date:  2021-02-28

Review 5.  Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches.

Authors:  Tiago M A Carvalho; Daria Di Molfetta; Maria Raffaella Greco; Tomas Koltai; Khalid O Alfarouk; Stephan J Reshkin; Rosa A Cardone
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

6.  Altered TGFB1 regulated pathways promote accelerated tendon healing in the superhealer MRL/MpJ mouse.

Authors:  Jacob G Kallenbach; Margaret A T Freeberg; David Abplanalp; Rahul G Alenchery; Raquel E Ajalik; Samantha Muscat; Jacquelyn A Myers; John M Ashton; Alayna Loiselle; Mark R Buckley; Andre J van Wijnen; Hani A Awad
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

7.  Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin.

Authors:  Helena Branco; Júlio Oliveira; Catarina Antunes; Lúcio L Santos; Maria Helena Vasconcelos; Cristina P R Xavier
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

8.  Therapeutic Effect of Gypenosides on Antioxidant Stress Injury in Orbital Fibroblasts of Graves' Orbitopathy.

Authors:  Chao Ma; Haoyu Li; Wei Liu; Shuwen Lu; Xian Li; Jinyuan Chen; Kaijun Li; Wenzhan Wang
Journal:  J Immunol Res       Date:  2022-09-15       Impact factor: 4.493

Review 9.  Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma.

Authors:  Rita Rebelo; Bárbara Polónia; Lúcio Lara Santos; M Helena Vasconcelos; Cristina P R Xavier
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-20

Review 10.  Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts.

Authors:  Farhana Mollah; Pegah Varamini
Journal:  Biomedicines       Date:  2021-12-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.